IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Inclusion Criteria:

Acute myeloid leukemia diagnosed according to WHO criteria with one of the following:

Primary refractory disease following ≥ 1 round of induction chemotherapy
First relapse or higher
Age between 18 and 70 years
ECOG performance status ≤ 2

Adequate organ function defined as:

Creatinine ≤ 1.5 x institutional ULN
AST ≤ 2 x ULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia)
ALT ≤ 2 x ULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia)
Total bilirubin ≤ 2 x ULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia)
Left ventricular ejection fraction of ≥ 40% by MUGA scan or echocardiogram
Women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study
Able to provide signed informed consent prior to registration on study

Exclusion Criteria:

Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)
Peripheral blood blast count ≥ 50 x 103 /mm3
Active CNS involvement with leukemia
Previous treatment with MEC or other regimen containing both mitoxantrone and etoposide
Pregnant or nursing
Concurrently receiving any other investigational agent
Received colony stimulating factors filgrastim or sargramostim within 48 hours or pegfilgrastim within 14 days of study
Less than 2 weeks from the completion of any previous cytotoxic chemotherapy (excluding hydroxyurea)
Severe concurrent illness that would limit compliance with study requirements